CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced it has signed a Commercial Supply Agreement with Precision Pharma Services, Inc. Under the Agreement, Precision will manufacture vials of Javelin’s injectable Dyloject™ product (diclofenac sodium 75mg / 2mL) for use in Javelin’s anticipated European markets pending regulatory approval. The Agreement has a two-year, renewable term and sets forth minimum purchase and production requirements.
